

Xeljanz XR - (22 mg, Tablet; Extended release)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | tofacitinib | Innovator | Pfizer |
| Dosage | 22 mg, Tablet; Extended release | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | It is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.